<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00784134</url>
  </required_header>
  <id_info>
    <org_study_id>IVH06</org_study_id>
    <secondary_id>5U01NS062851-05</secondary_id>
    <nct_id>NCT00784134</nct_id>
  </id_info>
  <brief_title>Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III</brief_title>
  <acronym>CLEAR III</acronym>
  <official_title>Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emissary International LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this Phase III clinical trial is to obtain information from a
      population of 500 ICH subjects with intraventricular hemorrhage (IVH), representative of
      current clinical practice and national demographics of ICH regarding the benefit (or lack
      thereof) of IVH clot removal on subject function as measured by modified Rankin Scale (mRS).
      This application requests funding for five years to initiate a Phase III randomized clinical
      trial (RCT) testing the benefit of clot removal for intraventricular hemorrhage. The
      investigators propose to compare extraventricular drainage (EVD) use plus recombinant tissue
      plasminogen activator (rt-PA; Alteplase; Genentech, Inc., San Francisco, CA) with EVD+
      placebo in the management and treatment of subjects with small intracerebral hemorrhage (ICH)
      and large intraventricular hemorrhage (IVH defined as ICH &lt; 30 cc and obstruction of the 3rd
      or 4th ventricles by intraventricular blood clot).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With Modified Rankin Scale (mRS) &lt;=3 - Dichotomized Analysis</measure>
    <time_frame>180 days</time_frame>
    <description>Analysis modified on September 29, 2015 to account for adaptive randomization. The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant Score on the Modified Rankin Scale (mRS) - Ordinal Analysis</measure>
    <time_frame>180 days</time_frame>
    <description>The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Modified Rankin Scale (mRS) &lt;=4 - Dichotomized Analysis</measure>
    <time_frame>180 days</time_frame>
    <description>The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Random Effects Assessment of Site Effect on Modified Rankin Scale (mRS) &lt;= 3</measure>
    <time_frame>180 days</time_frame>
    <description>The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Longitudinal Assessment of Participants With Modified Rankin Scale (mRS) &lt;=3</measure>
    <time_frame>30 days and 180 days</time_frame>
    <description>Comparing longitudinal modified Rankin Scale (mRS) scores 0-3 at Day 30 and Day 180. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clot Removal (Amount of Residual Blood)</measure>
    <time_frame>72 hours</time_frame>
    <description>Change in blood volume measured between stability scan and end of treatment scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Critical Care Management - Hospital Days</measure>
    <time_frame>30 days</time_frame>
    <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Critical Care Management - ICU Days</measure>
    <time_frame>30 days</time_frame>
    <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Critical Care Management - ICP Management</measure>
    <time_frame>30 days</time_frame>
    <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Critical Care Management - Mechanical Ventilation</measure>
    <time_frame>30 days</time_frame>
    <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Critical Care Management - Pressors</measure>
    <time_frame>30 days</time_frame>
    <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Critical Care Management - Shunts</measure>
    <time_frame>30 days</time_frame>
    <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Critical Care Management - All Infections</measure>
    <time_frame>30 days</time_frame>
    <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Critical Care Management - Pneumonia</measure>
    <time_frame>30 days</time_frame>
    <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Critical Care Management - All Infections</measure>
    <time_frame>180 days</time_frame>
    <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety/Mortality - Mortality Within 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>Frequency of bacterial brain infections, symptomatic brain bleeds, and mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety/Mortality - Bacterial Brain Infections Within 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>Frequency of bacterial brain infections, symptomatic brain bleeds, and mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety/Mortality - Systematic Bleeds Within 72 Hours</measure>
    <time_frame>72 hours</time_frame>
    <description>Frequency of bacterial brain infections, symptomatic brain bleeds, and mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety/Mortality - Systematic Bleeds Within 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>Frequency of bacterial brain infections, symptomatic brain bleeds, and mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse and Serious Adverse Events</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of number of adverse and serious adverse events by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predicting Hazards of Death by Treatment Group</measure>
    <time_frame>180 days</time_frame>
    <description>Cox Proportional Hazards Model is used to predict the hazards ratio by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Race (African-American)</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Race (White)</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Gender (Female)</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Gender (Male)</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Age (65 Years or Under)</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Age (Over 65 Years)</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by IVH Size (Less Than 20ml)</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by IVH Size (20-50ml)</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by IVH Size (Greater Than 50ml)</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Location (Thalamic)</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Location (Non-Thalamic)</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status - Barthel Index</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of NIHSS, Barthel Index, eGOS (dichotomy and ordinal) by group. The Barthel Index (BI) assesses ten functional tasks of daily living, and each task provides a measure for level of independence. Scores range from 0 and 100, with a higher score indicating greater independence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status - Participants With Extended Glasgow Outcome (eGOS) Score &gt;=Upper Severe Disability</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of NIHSS, Barthel Index, eGOS (dichotomy and ordinal) by group. The extended Glasgow Outcome Scale (eGOS) is a global scale for functional outcome with eight categories: 1 - Death, 2 - Vegetative State, 3 - Lower Severe Disability, 4 - Upper Severe Disability, 5 - Lower Moderate Disability, 6 - Upper Moderate Disability, 7 - Lower Good Recovery, 8 - Upper Good Recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status - National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of NIHSS, Barthel Index, eGOS (dichotomy and ordinal) by group. The National Institutes of Health Stroke Scale (NIHSS) is a 15-item scale that assesses language, motor function, sensory loss, consciousness, visual fields, extraocular movements, coordination, neglect, and speech. It is scored from 0 (no stroke symptoms) to 42 (severe stroke).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Stroke Impact Scale (SIS) - Strength</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Stroke Impact Scale (SIS) - Mobility</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Stroke Impact Scale (SIS) - Hand Function</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Stroke Impact Scale (SIS) - Activities of Daily Living</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Stroke Impact Scale (SIS) - Communication</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Stroke Impact Scale (SIS) - Thinking</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Stroke Impact Scale (SIS) - Emotion</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Stroke Impact Scale (SIS) - Participation</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Stroke Impact Scale (SIS) - Recovery</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - EuroQol Visual Analogue Scale (EQ-VAS)</measure>
    <time_frame>180 days</time_frame>
    <description>Assessment of SIS and EuroQol Visual Analog Scale by group. EuroQol Visual Analogue Scale (EQ-VAS) is a self-reported measure of health status. It is a marked scale where individuals draw a line to indicate their health, with end points of 0 (the worst health you can imagine) and 100 (the best health you can imagine).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Intraventricular Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Alteplase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administration of alteplase via the intraventricular catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 ml of normal saline administered via the intraventricular catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
    <arm_group_label>Alteplase</arm_group_label>
    <other_name>Cathflo Activase</other_name>
    <other_name>rt-PA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
    <arm_group_label>Saline Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-80

          -  Symptom onset less than 24 hrs prior to diagnostic CT scan

          -  Spontaneous ICH less than or equal to 30 cc or primary IVH

          -  IVH obstructing 3rd and/or 4th ventricles

          -  ICH clot stability at 6 hours or more post IVC placement

          -  IVH clot stability at 6 hours or more post IVC placement

          -  Catheter tract bleeding stability 6 hours or more post IVC placement

          -  EVD placed per standard medical care

          -  SBP less than 200 mmHg sustained for 6 hours prior to drug administration

          -  Able to randomize within 72 hours of diagnostic CT scan

          -  Historical Rankin of 0 or 1

        Exclusion Criteria:

          -  Suspected or untreated ruptured cerebral aneurysm, AVM, or tumor

          -  Presence of a choroid plexus vascular malformation or Moyamoya

          -  Clotting disorders

          -  Platelet count less than 100,000, INR greater than 1.4

          -  Pregnancy

          -  Infratentorial hemorrhage

          -  SAH at clinical presentation

          -  ICH/IVH enlargement that cannot be stabilized in the treatment time window

          -  Ongoing internal bleeding

          -  Superficial or surface bleeding

          -  Prior enrollment in the study

          -  Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated

          -  Planned or simultaneous participation (between screening and Day-30) in another
             interventional medical investigation or clinical trial.

          -  No subject or legal representative to give written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel F. Hanley, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California - Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intercoastal Medical Center</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruan Neurology Clinical and Research Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Brain and Stroke Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springfield Neurological and Spine Institute</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Neuroscience Institute at JFK</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08818</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northshore University Hospital Long Island</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case-Western Reserve University Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Stroke Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, Southwestern, Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Jose, Joinville</name>
      <address>
        <city>Joinville</city>
        <state>Santa Catarina</state>
        <zip>89202165</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Pronto Socorro de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Ribeirao Preto</name>
      <address>
        <city>Ribeirão Preto</city>
        <zip>14015-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Paulo Universidade Federal de Sao Paulo / UNIFESP</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04039032</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute at McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Halle</name>
      <address>
        <city>Halle</city>
        <zip>D-06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>D-55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tubingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Szeged</name>
      <address>
        <city>Szeged</city>
        <state>Csongrad</state>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Honved Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pecs</name>
      <address>
        <city>Pecs</city>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Hebrew University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat-Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellvitge Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Zurich</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Inselpital, Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <state>Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle General Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southampton Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <link>
    <url>http://braininjuryoutcomes.com</url>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2008</study_first_submitted>
  <study_first_submitted_qc>October 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2008</study_first_posted>
  <results_first_submitted>March 30, 2017</results_first_submitted>
  <results_first_submitted_qc>June 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2017</results_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intraventricular hemorrhage thrombolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>Data repository-VISTA</doc_id>
      <doc_type>Data repository-VISTA</doc_type>
      <doc_url>http://vista.gla.ac.uk</doc_url>
      <doc_comment>when available</doc_comment>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://vista.gla.ac.uk</doc_url>
      <doc_comment>when available</doc_comment>
    </study_doc>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>http://vista.gla.ac.uk</doc_url>
      <doc_comment>when available</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Alteplase</title>
          <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
        </group>
        <group group_id="P2">
          <title>Saline Placebo</title>
          <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="251"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="245"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alteplase</title>
          <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
        </group>
        <group group_id="B2">
          <title>Saline Placebo</title>
          <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="249"/>
            <count group_id="B2" value="251"/>
            <count group_id="B3" value="500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="172"/>
                    <measurement group_id="B3" value="354"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="222"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="305"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With Modified Rankin Scale (mRS) &lt;=3 - Dichotomized Analysis</title>
        <description>Analysis modified on September 29, 2015 to account for adaptive randomization. The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
        <time_frame>180 days</time_frame>
        <population>All the non-missing mRS scores at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Modified Rankin Scale (mRS) &lt;=3 - Dichotomized Analysis</title>
          <description>Analysis modified on September 29, 2015 to account for adaptive randomization. The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
          <population>All the non-missing mRS scores at 180 days were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6"/>
                    <measurement group_id="O2" value="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.554</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.027</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.062</ci_lower_limit>
            <ci_upper_limit>0.115</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.465</p_value>
            <p_value_desc>Multivariable logit model adjusted for age, GCS, thalamus, stability ICH volume and stability IVH volume.</p_value_desc>
            <method>Multivariable Logit Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participant Score on the Modified Rankin Scale (mRS) - Ordinal Analysis</title>
        <description>The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
        <time_frame>180 days</time_frame>
        <population>All the non-missing mRS scores at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Score on the Modified Rankin Scale (mRS) - Ordinal Analysis</title>
          <description>The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
          <population>All the non-missing mRS scores at 180 days were analyzed.</population>
          <units>mRS score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.484</p_value>
            <p_value_desc>Generalized ordered logit model adjusted for age, GCS, thalamus, stability ICH volume and stability IVH volume (categorical) compares odds ratio for mRS score &gt; K v. &lt;= K for K = 1 - 4; Alt v. Sal.</p_value_desc>
            <method>Generalized ordered Logit Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The same generalized ordered logit model, adjusting for age, GCS, thalamus, stability ICH volume and stability IVH volume (categorical), compares odds ratio for mRS score greater than 5 versus mRS score equal or less than 5 (dead versus alive).</p_value_desc>
            <method>Generalized ordered Logit Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Modified Rankin Scale (mRS) &lt;=4 - Dichotomized Analysis</title>
        <description>The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
        <time_frame>180 days</time_frame>
        <population>All the non-missing mRS scores at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Modified Rankin Scale (mRS) &lt;=4 - Dichotomized Analysis</title>
          <description>The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
          <population>All the non-missing mRS scores at 180 days were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2"/>
                    <measurement group_id="O2" value="61.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.552</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.026</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.059</ci_lower_limit>
            <ci_upper_limit>0.111</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.350</p_value>
            <p_value_desc>Multivariable logit model adjusting for age, GCS, thalamus, stability ICH volume and stability IVH volume (categorical).</p_value_desc>
            <method>Multivariable Logit Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Random Effects Assessment of Site Effect on Modified Rankin Scale (mRS) &lt;= 3</title>
        <description>The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
        <time_frame>180 days</time_frame>
        <population>All the non-missing mRS scores at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Random Effects Assessment of Site Effect on Modified Rankin Scale (mRS) &lt;= 3</title>
          <description>The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
          <population>All the non-missing mRS scores at 180 days were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6"/>
                    <measurement group_id="O2" value="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.428</p_value>
            <p_value_desc>Random effects model with site as random effect adjusted for age, GCS, thalamus, stability ICH volume and stability IVH volume (categorical).</p_value_desc>
            <method>Random Effects Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Longitudinal Assessment of Participants With Modified Rankin Scale (mRS) &lt;=3</title>
        <description>Comparing longitudinal modified Rankin Scale (mRS) scores 0-3 at Day 30 and Day 180. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
        <time_frame>30 days and 180 days</time_frame>
        <population>All the non-missing mRS scores at 30 days and 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Longitudinal Assessment of Participants With Modified Rankin Scale (mRS) &lt;=3</title>
          <description>Comparing longitudinal modified Rankin Scale (mRS) scores 0-3 at Day 30 and Day 180. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
          <population>All the non-missing mRS scores at 30 days and 180 days were analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="245"/>
                    <count group_id="O2" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4"/>
                    <measurement group_id="O2" value="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="245"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0"/>
                    <measurement group_id="O2" value="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logit mRS scores 0-3 at 30 days</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.384</p_value>
            <method>Generalized Estimating Equation Model</method>
            <method_desc>Generalized estimating equation model adjusting for age, GCS, thalamus, stability ICH volume and stability IVH volume (categorical).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logit mRS scores 0-3 at 180 days</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.964</p_value>
            <method>Generalized Estimating Equation Model</method>
            <method_desc>Generalized estimating equation model adjusting for age, GCS, thalamus, stability ICH volume and stability IVH volume (categorical).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <time_frame>180 days</time_frame>
        <population>All patients that were enrolled in CLEAR III were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <population>All patients that were enrolled in CLEAR III were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5"/>
                    <measurement group_id="O2" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0056</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clot Removal (Amount of Residual Blood)</title>
        <description>Change in blood volume measured between stability scan and end of treatment scan</description>
        <time_frame>72 hours</time_frame>
        <population>All patients that were enrolled in CLEAR III were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Clot Removal (Amount of Residual Blood)</title>
          <description>Change in blood volume measured between stability scan and end of treatment scan</description>
          <population>All patients that were enrolled in CLEAR III were analyzed.</population>
          <units>odds ratio per time-weighted ml</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96"/>
                    <measurement group_id="O2" value="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>AUC/ Logit Model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensity of Critical Care Management - Hospital Days</title>
        <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
        <time_frame>30 days</time_frame>
        <population>All patients that were enrolled in CLEAR III were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of Critical Care Management - Hospital Days</title>
          <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
          <population>All patients that were enrolled in CLEAR III were analyzed.</population>
          <units>Number of days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="17" upper_limit="31"/>
                    <measurement group_id="O2" value="24" lower_limit="16" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.771</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensity of Critical Care Management - ICU Days</title>
        <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
        <time_frame>30 days</time_frame>
        <population>All patients that were enrolled in CLEAR III were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of Critical Care Management - ICU Days</title>
          <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
          <population>All patients that were enrolled in CLEAR III were analyzed.</population>
          <units>Number of days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="11" upper_limit="21"/>
                    <measurement group_id="O2" value="15" lower_limit="12" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.098</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensity of Critical Care Management - ICP Management</title>
        <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
        <time_frame>30 days</time_frame>
        <population>All patients that were enrolled in CLEAR III were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of Critical Care Management - ICP Management</title>
          <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
          <population>All patients that were enrolled in CLEAR III were analyzed.</population>
          <units>Percentage of events of ICP &gt;20mmHg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.450</p_value>
            <method>Generalized Linear Models</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensity of Critical Care Management - Mechanical Ventilation</title>
        <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
        <time_frame>30 days</time_frame>
        <population>All patients that were enrolled in CLEAR III were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of Critical Care Management - Mechanical Ventilation</title>
          <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
          <population>All patients that were enrolled in CLEAR III were analyzed.</population>
          <units>% of participants with ventilation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9"/>
                    <measurement group_id="O2" value="76.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.501</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensity of Critical Care Management - Pressors</title>
        <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
        <time_frame>30 days</time_frame>
        <population>All patients that were enrolled in CLEAR III were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of Critical Care Management - Pressors</title>
          <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
          <population>All patients that were enrolled in CLEAR III were analyzed.</population>
          <units>% of participants with pressors</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1"/>
                    <measurement group_id="O2" value="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.795</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensity of Critical Care Management - Shunts</title>
        <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
        <time_frame>30 days</time_frame>
        <population>All patients that were enrolled in CLEAR III were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of Critical Care Management - Shunts</title>
          <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
          <population>All patients that were enrolled in CLEAR III were analyzed.</population>
          <units>% of participants with shunts</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5"/>
                    <measurement group_id="O2" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.784</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensity of Critical Care Management - All Infections</title>
        <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
        <time_frame>30 days</time_frame>
        <population>All patients that were enrolled in CLEAR III were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of Critical Care Management - All Infections</title>
          <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
          <population>All patients that were enrolled in CLEAR III were analyzed.</population>
          <units>% of participants with infections</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2"/>
                    <measurement group_id="O2" value="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.592</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensity of Critical Care Management - Pneumonia</title>
        <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
        <time_frame>30 days</time_frame>
        <population>All patients that were enrolled in CLEAR III were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of Critical Care Management - Pneumonia</title>
          <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
          <population>All patients that were enrolled in CLEAR III were analyzed.</population>
          <units>% of participants with pneumonia</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1"/>
                    <measurement group_id="O2" value="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.105</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensity of Critical Care Management - All Infections</title>
        <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
        <time_frame>180 days</time_frame>
        <population>All patients that were enrolled in CLEAR III were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of Critical Care Management - All Infections</title>
          <description>Intensity of critical care management as measured by hospital and ICU length of stay, frequency of ICP &gt;20 mmHg events, use of mechanical ventilation, pressors, and ventriculoperitioneal shunts, frequency of systemic infections.</description>
          <population>All patients that were enrolled in CLEAR III were analyzed.</population>
          <units>% of participants with infections</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8"/>
                    <measurement group_id="O2" value="56.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.152</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety/Mortality - Mortality Within 30 Days</title>
        <description>Frequency of bacterial brain infections, symptomatic brain bleeds, and mortality.</description>
        <time_frame>30 days</time_frame>
        <population>All patients that were enrolled in CLEAR III were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Safety/Mortality - Mortality Within 30 Days</title>
          <description>Frequency of bacterial brain infections, symptomatic brain bleeds, and mortality.</description>
          <population>All patients that were enrolled in CLEAR III were analyzed.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.055</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.055</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.111</ci_lower_limit>
            <ci_upper_limit>0.008</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety/Mortality - Bacterial Brain Infections Within 30 Days</title>
        <description>Frequency of bacterial brain infections, symptomatic brain bleeds, and mortality.</description>
        <time_frame>30 days</time_frame>
        <population>All patients that were enrolled in CLEAR III were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Safety/Mortality - Bacterial Brain Infections Within 30 Days</title>
          <description>Frequency of bacterial brain infections, symptomatic brain bleeds, and mortality.</description>
          <population>All patients that were enrolled in CLEAR III were analyzed.</population>
          <units>% of participants with brain infection</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.202</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.035</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.084</ci_lower_limit>
            <ci_upper_limit>0.014</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety/Mortality - Systematic Bleeds Within 72 Hours</title>
        <description>Frequency of bacterial brain infections, symptomatic brain bleeds, and mortality.</description>
        <time_frame>72 hours</time_frame>
        <population>All patients that were enrolled in CLEAR III were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Safety/Mortality - Systematic Bleeds Within 72 Hours</title>
          <description>Frequency of bacterial brain infections, symptomatic brain bleeds, and mortality.</description>
          <population>All patients that were enrolled in CLEAR III were analyzed.</population>
          <units>% of participants with systematic bleeds</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.771</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.004</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.022</ci_lower_limit>
            <ci_upper_limit>0.030</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety/Mortality - Systematic Bleeds Within 30 Days</title>
        <description>Frequency of bacterial brain infections, symptomatic brain bleeds, and mortality.</description>
        <time_frame>30 days</time_frame>
        <population>All patients that were enrolled in CLEAR III were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Safety/Mortality - Systematic Bleeds Within 30 Days</title>
          <description>Frequency of bacterial brain infections, symptomatic brain bleeds, and mortality.</description>
          <population>All patients that were enrolled in CLEAR III were analyzed.</population>
          <units>% of participants with systematic bleeds</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.811</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.004</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.028</ci_lower_limit>
            <ci_upper_limit>0.036</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse and Serious Adverse Events</title>
        <description>Assessment of number of adverse and serious adverse events by treatment group.</description>
        <time_frame>180 days</time_frame>
        <population>All patients that were enrolled in CLEAR III were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse and Serious Adverse Events</title>
          <description>Assessment of number of adverse and serious adverse events by treatment group.</description>
          <population>All patients that were enrolled in CLEAR III were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8"/>
                    <measurement group_id="O2" value="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0017</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.144</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.230</ci_lower_limit>
            <ci_upper_limit>-0.057</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predicting Hazards of Death by Treatment Group</title>
        <description>Cox Proportional Hazards Model is used to predict the hazards ratio by treatment group.</description>
        <time_frame>180 days</time_frame>
        <population>All patients that were enrolled in CLEAR III were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Predicting Hazards of Death by Treatment Group</title>
          <description>Cox Proportional Hazards Model is used to predict the hazards ratio by treatment group.</description>
          <population>All patients that were enrolled in CLEAR III were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5"/>
                    <measurement group_id="O2" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Adjusted Cox Proportional Hazards Model adjusting for age, GCS, thalamus, stability ICH volume and stability IVH volume (categorical).</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Race (African-American)</title>
        <description>Assessment of modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
        <time_frame>180 days</time_frame>
        <population>All patients that reported they were African-American with a non-missing mRS score at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Race (African-American)</title>
          <description>Assessment of modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
          <population>All patients that reported they were African-American with a non-missing mRS score at 180 days were analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.4"/>
                    <measurement group_id="O2" value="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.410</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.064</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.088</ci_lower_limit>
            <ci_upper_limit>0.217</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Race (White)</title>
        <description>Assessment of modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
        <time_frame>180 days</time_frame>
        <population>All patients that reported they were White with a non-missing mRS score at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Race (White)</title>
          <description>Assessment of modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
          <population>All patients that reported they were White with a non-missing mRS score at 180 days were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.4"/>
                    <measurement group_id="O2" value="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.781</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.016</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.096</ci_lower_limit>
            <ci_upper_limit>0.128</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Gender (Female)</title>
        <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
        <time_frame>180 days</time_frame>
        <population>All female patients with a non-missing mRS score at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Gender (Female)</title>
          <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
          <population>All female patients with a non-missing mRS score at 180 days were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6"/>
                    <measurement group_id="O2" value="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.773</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.020</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.113</ci_lower_limit>
            <ci_upper_limit>0.152</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Gender (Male)</title>
        <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
        <time_frame>180 days</time_frame>
        <population>All male patients with a non-missing mRS score at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Gender (Male)</title>
          <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
          <population>All male patients with a non-missing mRS score at 180 days were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6"/>
                    <measurement group_id="O2" value="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.587</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.032</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.085</ci_lower_limit>
            <ci_upper_limit>0.151</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Age (65 Years or Under)</title>
        <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
        <time_frame>180 days</time_frame>
        <population>All patients 65 years of age or under with a non-missing mRS score at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Age (65 Years or Under)</title>
          <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
          <population>All patients 65 years of age or under with a non-missing mRS score at 180 days were analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6"/>
                    <measurement group_id="O2" value="52.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.775</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.015</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.121</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Age (Over 65 Years)</title>
        <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
        <time_frame>180 days</time_frame>
        <population>All patients over 65 years of age with a non-missing mRS score at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Age (Over 65 Years)</title>
          <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
          <population>All patients over 65 years of age with a non-missing mRS score at 180 days were analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3"/>
                    <measurement group_id="O2" value="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.808</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.019</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.132</ci_lower_limit>
            <ci_upper_limit>0.169</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by IVH Size (Less Than 20ml)</title>
        <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
        <time_frame>180 days</time_frame>
        <population>All patients with an IVH size less than 20ml and a non-missing mRS score at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by IVH Size (Less Than 20ml)</title>
          <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
          <population>All patients with an IVH size less than 20ml and a non-missing mRS score at 180 days were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.1"/>
                    <measurement group_id="O2" value="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.625</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.033</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.165</ci_lower_limit>
            <ci_upper_limit>0.099</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by IVH Size (20-50ml)</title>
        <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
        <time_frame>180 days</time_frame>
        <population>All patients with an IVH size between 20ml and 50ml and a non-missing mRS score at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by IVH Size (20-50ml)</title>
          <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
          <population>All patients with an IVH size between 20ml and 50ml and a non-missing mRS score at 180 days were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3"/>
                    <measurement group_id="O2" value="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.191</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.087</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.043</ci_lower_limit>
            <ci_upper_limit>0.218</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by IVH Size (Greater Than 50ml)</title>
        <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
        <time_frame>180 days</time_frame>
        <population>All patients with an IVH size greater than 50ml and a non-missing mRS score at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by IVH Size (Greater Than 50ml)</title>
          <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
          <population>All patients with an IVH size greater than 50ml and a non-missing mRS score at 180 days were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5"/>
                    <measurement group_id="O2" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.949</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.0066</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.197</ci_lower_limit>
            <ci_upper_limit>0.211</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Location (Thalamic)</title>
        <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
        <time_frame>180 days</time_frame>
        <population>All patients with a thalamic blood clot location and a non-missing mRS score at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Location (Thalamic)</title>
          <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
          <population>All patients with a thalamic blood clot location and a non-missing mRS score at 180 days were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8"/>
                    <measurement group_id="O2" value="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.812</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.014</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.098</ci_lower_limit>
            <ci_upper_limit>0.126</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Location (Non-Thalamic)</title>
        <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
        <time_frame>180 days</time_frame>
        <population>All patients with a non-thalamic blood clot location and a non-missing mRS score at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Sub-Group Analyses - Difference in Modified Rankin Scale (mRS) 0-3 Proportion by Location (Non-Thalamic)</title>
          <description>Assessment of Modified Rankin Scale (mRS) score 0-3 compared by race, gender, age, IVH size, and ICH location. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 (perfect health without symptoms) to 6 (death).</description>
          <population>All patients with a non-thalamic blood clot location and a non-missing mRS score at 180 days were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.6"/>
                    <measurement group_id="O2" value="54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.394</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.059</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.076</ci_lower_limit>
            <ci_upper_limit>0.194</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Status - Barthel Index</title>
        <description>Assessment of NIHSS, Barthel Index, eGOS (dichotomy and ordinal) by group. The Barthel Index (BI) assesses ten functional tasks of daily living, and each task provides a measure for level of independence. Scores range from 0 and 100, with a higher score indicating greater independence.</description>
        <time_frame>180 days</time_frame>
        <population>All the non-missing Barthel scores at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Status - Barthel Index</title>
          <description>Assessment of NIHSS, Barthel Index, eGOS (dichotomy and ordinal) by group. The Barthel Index (BI) assesses ten functional tasks of daily living, and each task provides a measure for level of independence. Scores range from 0 and 100, with a higher score indicating greater independence.</description>
          <population>All the non-missing Barthel scores at 180 days were analyzed.</population>
          <units>Barthel score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2" spread="37.7"/>
                    <measurement group_id="O2" value="69.5" spread="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.312</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Status - Participants With Extended Glasgow Outcome (eGOS) Score &gt;=Upper Severe Disability</title>
        <description>Assessment of NIHSS, Barthel Index, eGOS (dichotomy and ordinal) by group. The extended Glasgow Outcome Scale (eGOS) is a global scale for functional outcome with eight categories: 1 - Death, 2 - Vegetative State, 3 - Lower Severe Disability, 4 - Upper Severe Disability, 5 - Lower Moderate Disability, 6 - Upper Moderate Disability, 7 - Lower Good Recovery, 8 - Upper Good Recovery.</description>
        <time_frame>180 days</time_frame>
        <population>All the non-missing eGOS scores at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Status - Participants With Extended Glasgow Outcome (eGOS) Score &gt;=Upper Severe Disability</title>
          <description>Assessment of NIHSS, Barthel Index, eGOS (dichotomy and ordinal) by group. The extended Glasgow Outcome Scale (eGOS) is a global scale for functional outcome with eight categories: 1 - Death, 2 - Vegetative State, 3 - Lower Severe Disability, 4 - Upper Severe Disability, 5 - Lower Moderate Disability, 6 - Upper Moderate Disability, 7 - Lower Good Recovery, 8 - Upper Good Recovery.</description>
          <population>All the non-missing eGOS scores at 180 days were analyzed.</population>
          <units>% of participants with score&gt;=4</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.087</p_value>
            <p_value_desc>Analysis of dichotomous eGOS, comparing Upper Severe Disability scores to Lower Severe Disability scores</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.075</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.011</ci_lower_limit>
            <ci_upper_limit>0.160</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.064</p_value>
            <p_value_desc>Adjusted Multivariable Logit Model comparing eGOS scores of Upper Severe Disability or greater versus Lower Severe Disability and worse; Alteplase versus Saline</p_value_desc>
            <method>Multivariable Logit Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>2.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.336</p_value>
            <p_value_desc>Adjusted generalized ordered logit model odds ratios for eGOS scores of Moderate Disability or worse versus Good Recovery; Alteplase versus Saline</p_value_desc>
            <method>Generalized Ordered Logit Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>2.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.783</p_value>
            <p_value_desc>Adjusted generalized ordered logit model odds ratios for eGOS scores of Upper Severe Disability or worse versus Moderate Disability + Good Recovery; Alteplase versus Saline</p_value_desc>
            <method>Generalized Ordered Logit Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Status - National Institutes of Health Stroke Scale (NIHSS)</title>
        <description>Assessment of NIHSS, Barthel Index, eGOS (dichotomy and ordinal) by group. The National Institutes of Health Stroke Scale (NIHSS) is a 15-item scale that assesses language, motor function, sensory loss, consciousness, visual fields, extraocular movements, coordination, neglect, and speech. It is scored from 0 (no stroke symptoms) to 42 (severe stroke).</description>
        <time_frame>180 days</time_frame>
        <population>All the non-missing NIHSS scores at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Status - National Institutes of Health Stroke Scale (NIHSS)</title>
          <description>Assessment of NIHSS, Barthel Index, eGOS (dichotomy and ordinal) by group. The National Institutes of Health Stroke Scale (NIHSS) is a 15-item scale that assesses language, motor function, sensory loss, consciousness, visual fields, extraocular movements, coordination, neglect, and speech. It is scored from 0 (no stroke symptoms) to 42 (severe stroke).</description>
          <population>All the non-missing NIHSS scores at 180 days were analyzed.</population>
          <units>NIHSS score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - Stroke Impact Scale (SIS) - Strength</title>
        <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
        <time_frame>180 days</time_frame>
        <population>All the non-missing SIS scores at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - Stroke Impact Scale (SIS) - Strength</title>
          <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
          <population>All the non-missing SIS scores at 180 days were analyzed.</population>
          <units>SIS score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.97" spread="35.37"/>
                    <measurement group_id="O2" value="58.75" spread="34.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.312</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - Stroke Impact Scale (SIS) - Mobility</title>
        <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
        <time_frame>180 days</time_frame>
        <population>All the non-missing SIS scores at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - Stroke Impact Scale (SIS) - Mobility</title>
          <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
          <population>All the non-missing SIS scores at 180 days were analyzed.</population>
          <units>SIS score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.30" spread="38.16"/>
                    <measurement group_id="O2" value="60.10" spread="36.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - Stroke Impact Scale (SIS) - Hand Function</title>
        <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
        <time_frame>180 days</time_frame>
        <population>All the non-missing SIS scores at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - Stroke Impact Scale (SIS) - Hand Function</title>
          <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
          <population>All the non-missing SIS scores at 180 days were analyzed.</population>
          <units>SIS score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.41" spread="41.86"/>
                    <measurement group_id="O2" value="56.52" spread="39.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.478</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - Stroke Impact Scale (SIS) - Activities of Daily Living</title>
        <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
        <time_frame>180 days</time_frame>
        <population>All the non-missing SIS scores at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - Stroke Impact Scale (SIS) - Activities of Daily Living</title>
          <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
          <population>All the non-missing SIS scores at 180 days were analyzed.</population>
          <units>SIS score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.33" spread="37.90"/>
                    <measurement group_id="O2" value="61.19" spread="34.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.634</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - Stroke Impact Scale (SIS) - Communication</title>
        <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
        <time_frame>180 days</time_frame>
        <population>All the non-missing SIS scores at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - Stroke Impact Scale (SIS) - Communication</title>
          <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
          <population>All the non-missing SIS scores at 180 days were analyzed.</population>
          <units>SIS score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.02" spread="31.47"/>
                    <measurement group_id="O2" value="79.60" spread="26.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.255</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - Stroke Impact Scale (SIS) - Thinking</title>
        <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
        <time_frame>180 days</time_frame>
        <population>All the non-missing SIS scores at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - Stroke Impact Scale (SIS) - Thinking</title>
          <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
          <population>All the non-missing SIS scores at 180 days were analyzed.</population>
          <units>SIS score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.48" spread="33.11"/>
                    <measurement group_id="O2" value="62.68" spread="31.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.224</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - Stroke Impact Scale (SIS) - Emotion</title>
        <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
        <time_frame>180 days</time_frame>
        <population>All the non-missing SIS scores at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - Stroke Impact Scale (SIS) - Emotion</title>
          <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
          <population>All the non-missing SIS scores at 180 days were analyzed.</population>
          <units>SIS score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.14" spread="19.62"/>
                    <measurement group_id="O2" value="73.45" spread="20.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.882</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - Stroke Impact Scale (SIS) - Participation</title>
        <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
        <time_frame>180 days</time_frame>
        <population>All the non-missing SIS scores at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - Stroke Impact Scale (SIS) - Participation</title>
          <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
          <population>All the non-missing SIS scores at 180 days were analyzed.</population>
          <units>SIS score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.46" spread="33.01"/>
                    <measurement group_id="O2" value="49.58" spread="33.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.551</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - Stroke Impact Scale (SIS) - Recovery</title>
        <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
        <time_frame>180 days</time_frame>
        <population>All the non-missing SIS scores at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - Stroke Impact Scale (SIS) - Recovery</title>
          <description>Assessment of SIS and EuroQol Visual Analog Scale by group. The Stroke Impact Scale (SIS) covers 8 dimensions of stroke outcomes: strength, hand function, activities of daily living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking, participation. It is scored on a scale of 0 to 100 for each dimension, with higher scores indicating better self-reported health.</description>
          <population>All the non-missing SIS scores at 180 days were analyzed.</population>
          <units>SIS score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.04" spread="26.42"/>
                    <measurement group_id="O2" value="63.44" spread="25.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.224</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - EuroQol Visual Analogue Scale (EQ-VAS)</title>
        <description>Assessment of SIS and EuroQol Visual Analog Scale by group. EuroQol Visual Analogue Scale (EQ-VAS) is a self-reported measure of health status. It is a marked scale where individuals draw a line to indicate their health, with end points of 0 (the worst health you can imagine) and 100 (the best health you can imagine).</description>
        <time_frame>180 days</time_frame>
        <population>All the non-missing EuroQol scores at 180 days were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - EuroQol Visual Analogue Scale (EQ-VAS)</title>
          <description>Assessment of SIS and EuroQol Visual Analog Scale by group. EuroQol Visual Analogue Scale (EQ-VAS) is a self-reported measure of health status. It is a marked scale where individuals draw a line to indicate their health, with end points of 0 (the worst health you can imagine) and 100 (the best health you can imagine).</description>
          <population>All the non-missing EuroQol scores at 180 days were analyzed.</population>
          <units>EuroQol score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.8" spread="26.0"/>
                    <measurement group_id="O2" value="65.1" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.376</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>180 days since symptom onset</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Alteplase</title>
          <description>Administration of alteplase via the intraventricular catheter
Alteplase: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
        </group>
        <group group_id="E2">
          <title>Saline Placebo</title>
          <description>1 ml of normal saline administered via the intraventricular catheter
Normal saline: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Asystole</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="249"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Intercardiac clot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Supraventricular tachydysrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Takotsubo syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Colonic perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Duodenal hemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Esophageal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Gastric hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Gastroparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular death (brain death)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Death due to index bleeding event</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="249"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Sudden death NOS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="249"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Intrahepatic cholestasis of unk etiology</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Peritoneal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="249"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Ventriculitis, bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Ventriculitis, non-bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Wound infection, non-neurologic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Tracheostomy site bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus, Type I</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Muscle weakness left-sided</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Anoxic brain damage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Anoxic brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Brain and catheter related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Brainstorming/autonomic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Cerebrospinal fluid leakage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Cerebrovascular death (brain death)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Death due to index bleeding event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="249"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Diencephalic storming</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Edema cerebral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Extensor posturing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Herniation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hydrocephalus, communicating</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="249"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hydrocephalus, obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Intracranial abcess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage: Catheter Tract, Enlargement</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage: Catheter Tract, New</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="249"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage: Hematoma, subdural</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage: Subarachnoid Space, New</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage: Tissue, Enlargement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage: Tissue, New</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage: Ventricular system, Enlargement</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage: Ventricular system, New</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Intracranial hypertension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="249"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Reversible cerebral vasoconstriction vs vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="249"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>VP shunt dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Vasospasm or DIND</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Ventriculitis, bacterial</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Ventriculitis, non-bacterial</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="249"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Interstitial nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Renal calculi</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="249"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Laryngeal edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="249"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="249"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="249"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Tachypnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Tracheal mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>PEG Tube complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="249"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="76" subjects_affected="72" subjects_at_risk="249"/>
                <counts group_id="E2" events="74" subjects_affected="67" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="249"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="38" subjects_affected="36" subjects_at_risk="249"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="249"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hydrocephalus, communicating</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="249"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage: Catheter Tract, New</sub_title>
                <counts group_id="E1" events="37" subjects_affected="34" subjects_at_risk="249"/>
                <counts group_id="E2" events="47" subjects_affected="39" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Intracranial hypertension</sub_title>
                <counts group_id="E1" events="53" subjects_affected="39" subjects_at_risk="249"/>
                <counts group_id="E2" events="50" subjects_affected="42" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="249"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="249"/>
                <counts group_id="E2" events="53" subjects_affected="53" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="249"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel F. Hanley</name_or_title>
      <organization>Johns Hopkins University Division of Brain Injury Outcomes</organization>
      <phone>4106146996</phone>
      <email>dhanley@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

